Market closedNon-fractional
Kodiak Sciences/KOD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Kodiak Sciences
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Ticker
KOD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Palo Alto, United States
Employees
107
Website
kodiak.com
Kodiak Sciences Metrics
BasicAdvanced
$169M
Market cap
-
P/E ratio
-$4.44
EPS
2.24
Beta
-
Dividend rate
Price and volume
Market cap
$169M
Beta
2.24
Financial strength
Current ratio
10.119
Quick ratio
9.894
Long term debt to equity
28.49
Total debt to equity
32.472
Interest coverage (TTM)
-27,640.11%
Management effectiveness
Return on assets (TTM)
-28.92%
Return on equity (TTM)
-73.45%
Valuation
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-0.961
Growth
Earnings per share change (TTM)
-24.89%
3-year earnings per share growth (CAGR)
9.76%
What the Analysts think about Kodiak Sciences
Analyst Ratings
Majority rating from 7 analysts.
Kodiak Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$43M
-27.73%
Profit margin
0.00%
NaN%
Kodiak Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.53
-$0.95
-$1.13
-$0.82
-
Expected
-$1.14
-$1.21
-$0.77
-$1.07
-$0.87
Surprise
34.05%
-21.30%
46.12%
-23.24%
-
Kodiak Sciences News
AllArticlesVideos
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
PRNewsWire·2 months ago
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
PRNewsWire·2 months ago
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kodiak Sciences stock?
Kodiak Sciences (KOD) has a market cap of $169M as of July 26, 2024.
What is the P/E ratio for Kodiak Sciences stock?
The price to earnings (P/E) ratio for Kodiak Sciences (KOD) stock is 0 as of July 26, 2024.
Does Kodiak Sciences stock pay dividends?
No, Kodiak Sciences (KOD) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Kodiak Sciences dividend payment date?
Kodiak Sciences (KOD) stock does not pay dividends to its shareholders.
What is the beta indicator for Kodiak Sciences?
Kodiak Sciences (KOD) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Kodiak Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.